Blockade of the orexin-2 receptors within the ventral tegmental area facilitates the extinction and prevents the reinstatement of methamphetamine-seeking behavior. 2024

Ferdos Zamanirad, and Kiarash Eskandari, and Zahra Mousavi, and Abbas Haghparast
Pharmacology and Toxicology Department, Faculty of Pharmacy and Pharmaceutical Sciences, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.

Repeated use of methamphetamine (METH) causes severe effects on the central nervous system, associated with an increased relapse rate. The orexinergic system is highly implicated in the reward circuitry and may be a promising target for treating psychostimulant dependency. The present study aimed to investigate the involvement of the orexin system, mainly the orexin-2 receptors (OX2R) in the ventral tegmental area (VTA) in the extinction and reinstatement of METH-seeking behavior using a conditioned place preference (CPP) paradigm. To this end, animals received METH (1 mg/kg; sc) for a 5-day conditioning period. Then, in the first set of experiments, different groups of rats were given intra-VTA TCS OX2 29 (1, 3, 10, or 30 nmol/0.3 μl DMSO) as an OX2R antagonist over a 10-day extinction period. In another experiment, after the extinction period, a different set of animals received a single dose of TCS OX2 29 (1, 3, 10, or 30 nmol) before the priming dose of METH (0.25 mg/kg; sc) on the reinstatement day. The results revealed that TCS OX2 29 (10 and 30 nmol) remarkably facilitated the extinction of rewarding properties of METH (P < 0.001 for both doses). Furthermore, TCS OX2 29 (3, 10, or 30 nmol) significantly suppressed the METH-induced reinstatement (3 nmol; P < 0.05, 10 nmol; P < 0.01, and 30 nmol; P < 0.001). In conclusion, the current study revealed that the orexinergic system, specifically the VTA OX2R, is involved in METH-seeking behaviors and that manipulation of this system can be considered a potential therapeutics in treating METH dependency.

UI MeSH Term Description Entries

Related Publications

Ferdos Zamanirad, and Kiarash Eskandari, and Zahra Mousavi, and Abbas Haghparast
September 2023, Behavioural brain research,
Ferdos Zamanirad, and Kiarash Eskandari, and Zahra Mousavi, and Abbas Haghparast
February 2023, Neurochemical research,
Ferdos Zamanirad, and Kiarash Eskandari, and Zahra Mousavi, and Abbas Haghparast
April 2018, The international journal of neuropsychopharmacology,
Ferdos Zamanirad, and Kiarash Eskandari, and Zahra Mousavi, and Abbas Haghparast
January 2019, Frontiers in molecular neuroscience,
Ferdos Zamanirad, and Kiarash Eskandari, and Zahra Mousavi, and Abbas Haghparast
June 2011, The international journal of neuropsychopharmacology,
Ferdos Zamanirad, and Kiarash Eskandari, and Zahra Mousavi, and Abbas Haghparast
May 2009, Biological psychiatry,
Ferdos Zamanirad, and Kiarash Eskandari, and Zahra Mousavi, and Abbas Haghparast
February 2021, Behavioural pharmacology,
Ferdos Zamanirad, and Kiarash Eskandari, and Zahra Mousavi, and Abbas Haghparast
August 2016, European journal of pain (London, England),
Ferdos Zamanirad, and Kiarash Eskandari, and Zahra Mousavi, and Abbas Haghparast
March 2009, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
Ferdos Zamanirad, and Kiarash Eskandari, and Zahra Mousavi, and Abbas Haghparast
March 2015, Learning & memory (Cold Spring Harbor, N.Y.),
Copied contents to your clipboard!